-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
As the first product of WuXi Junuo, a class 1 new drug CAR-T product , Benoda® (Ruiji Orenza Injection), achieved the first patient reinfusion treatment in December 2017, and it will also be the first patient in 2022.
WuXi Junuo has successfully built a world-leading cellular immunotherapy technology and product development platform, as well as a product pipeline covering blood and solid tumors, and has carried out 9 clinical studies on blood and solid tumors
About Benoda® ( Rigiorenza Injection)
Benoda® (Ruiji Orenza Injection) is a CD19-targeting drug independently developed by WuXi Junuo on the basis of the CAR-T cell technology platform of Junuo Medical (a company of Bristol-Myers Squibb).
About WuXi Junuo
WuXi Junuo (HKEx: 2126) is an independent, innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products
Forward-Looking Statements
The forward-looking statements contained in this release are based on management's existing expectations and beliefs and are subject to certain uncertainties or risks that could cause actual results to differ materially from those described